Second and third line treatment in non-small cell lung cancer

Favaretto, Adolfo; Pasello, Giulia; Magro, Cristina; Schettino, Clorinda; Gridelli, Cesare

doi:10.1016/j.critrevonc.2009.01.009

Cited by 8 publications

(6 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between 19 and 30% of chemo-naive patients treated with one of these combinations achieves a response lasting 4-5 months (Favaretto et al 2009). However, patients with advanced NSCLC who initially respond will eventually progress and require second-line therapy.…”

Section: Introductionmentioning

confidence: 98%

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Tang

et al. 2012

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Tang

et al. 2012

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…First-line chemotherapy in advanced non-small-cell lung cancer (NSCLC) usually consists of a combination of a platinum compound (cisplatin or carboplatin) with a third-generation agent (paclitaxel, docetaxel, gemcitabine, pemetrexed, or vinorelbine) [2,3]. Between 19 and 30% of chemo-naive patients treated with one of these combinations achieves a response lasting 4-5 months [4]. Nonetheless, virtually all patients who initially respond will eventually progress.…”

Section: Introductionmentioning

confidence: 99%

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

et al. 2010

View full text Add to dashboard Cite

Because of improved therapeutic results after first-line platinum-based chemotherapy in patients with stage IV non-small-cell lung cancer (NSCLC), second-line chemotherapy may be considered for a growing number of patients. Approximately, 10% of patients have an interval time after concluding first-line platinum-based chemotherapy greater than 6 months. These patients may achieve high tumor responses when platinum is again used in second-line treatment. Twenty-three patients experiencing progression following 6 months after concluding platinum-based chemotherapy were managed with second-line treatment with carboplatin combined with gemcitabine or pemetrexed. Overall response, progression-free survival (PFS), and overall survival (OS) after initiation of second-line treatment were calculated for all patients. Median PFS after first-line treatment was 12.6 months (95% confidence interval [95% CI], 10.4-14.7 months). Partial response was achieved in 7 of 23 patients, resulting in an overall response of 30.4% (95% CI, 11.6-49.0). Following initiation of second-line chemotherapy, median PFS was 5.9 months (95% CI, 1-10.9 months) and median OS was 12.5 months (95% CI, 3.5-21.5 months). The 1-year survival rate for all patients was 61.0% (95% CI, 29.5-82.0). Adding these results to those of the 10 previously published trials, 75 of 326 patients, 23%, (95% CI, 18.7-27.3) presented an overall response with the use of second-line platinum-based chemotherapy. The use of platinum combinations as second-line chemotherapy seems to have a place in the management of patients with advanced NSCLC, especially those with an interval time to progression greater than 6 months.

show abstract

“…So for the majority of patients without driver mutations, platinum-based chemotherapy remains the standard first-line treatment (Natukula et al, In this subpopulation, patients are recommended to receive second-line chemotherapy such as doctacel or pemetrexed when first-line treatment fails (Hanna et al, 2004;Caponi et al, 2010;Ardizzoni et al, 2012) However, the efficacy of second-line chemotherapy is still dismal, with a response rate of about 10%, PFS of 2-3 months and OS of 6-9 months (Hanna et al, 2004;de Marinis et al, 2011;Ardizzoni et al, 2012). More importantly, currently, there are also still no identified predictive factors to predict the efficacy of second-line chemotherapy (Favaretto et al, 2009;de Marinis et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer

Cao

Li²,

Ren³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Second and third line treatment in non-small cell lung cancer

Cited by 8 publications

References 73 publications

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About